{"id":224,"date":"2022-02-18T10:02:20","date_gmt":"2022-02-18T10:02:20","guid":{"rendered":"https:\/\/kekkan-biologics.com\/?page_id=224"},"modified":"2022-02-18T11:23:52","modified_gmt":"2022-02-18T11:23:52","slug":"science-and-technology","status":"publish","type":"page","link":"https:\/\/kekkan-biologics.com\/index.php\/science-and-technology\/","title":{"rendered":"Science and Technology"},"content":{"rendered":"\n<h2 class=\"has-secondary-color has-text-color eplus-wrapper wp-block-heading\" id=\"our-approach\">Our Approach<\/h2>\n\n\n\n<div class=\"wp-block-image eplus-wrapper\"><figure class=\"aligncenter size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"530\" height=\"281\" src=\"https:\/\/kekkan-biologics.com\/wp-content\/uploads\/2022\/02\/image.png\" alt=\"\" class=\"wp-image-225\" srcset=\"https:\/\/kekkan-biologics.com\/wp-content\/uploads\/2022\/02\/image.png 530w, https:\/\/kekkan-biologics.com\/wp-content\/uploads\/2022\/02\/image-300x159.png 300w\" sizes=\"(max-width: 530px) 100vw, 530px\" \/><\/figure><\/div>\n\n\n\n<p class=\" eplus-wrapper\">Malignant tumors need blood vessels to get nutrients and oxygen, and they use lymphatic vessels to metastasize. Blocking validated targets in angiogenesis and lymphangiogenesis with highly specific and safe antibodies, deprives tumors of their ability to grow and metastasize.<\/p>\n\n\n\n<h2 class=\"has-secondary-color has-text-color eplus-wrapper wp-block-heading\" id=\"kb-platform\">KB Platform<\/h2>\n\n\n\n<blockquote class=\"wp-block-quote has-large-font-size eplus-wrapper is-layout-flow wp-block-quote-is-layout-flow\" style=\"font-style:normal;font-weight:100\"><p>Sophisticated target selection and mAb development designed to address multiple pathological mechanisms in parallel<\/p><\/blockquote>\n\n\n\n<div class=\"wp-block-image eplus-wrapper\"><figure class=\"aligncenter size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/kekkan-biologics.com\/wp-content\/uploads\/2022\/02\/image-1-1024x445.png\" alt=\"\" class=\"wp-image-226\" width=\"650\" height=\"282\" srcset=\"https:\/\/kekkan-biologics.com\/wp-content\/uploads\/2022\/02\/image-1-1024x445.png 1024w, https:\/\/kekkan-biologics.com\/wp-content\/uploads\/2022\/02\/image-1-300x130.png 300w, https:\/\/kekkan-biologics.com\/wp-content\/uploads\/2022\/02\/image-1-768x334.png 768w, https:\/\/kekkan-biologics.com\/wp-content\/uploads\/2022\/02\/image-1-1536x668.png 1536w, https:\/\/kekkan-biologics.com\/wp-content\/uploads\/2022\/02\/image-1.png 1898w\" sizes=\"(max-width: 650px) 100vw, 650px\" \/><\/figure><\/div>\n\n\n\n<h2 class=\"has-secondary-color has-text-color eplus-wrapper wp-block-heading\" id=\"kb-pipeline\">KB Pipeline<\/h2>\n\n\n\n<blockquote class=\"wp-block-quote has-large-font-size eplus-wrapper is-layout-flow wp-block-quote-is-layout-flow\" style=\"font-style:normal;font-weight:100\"><p>Portfolio of 3 patent protected mAb with promising in vivo Efficacy<\/p><\/blockquote>\n\n\n\n<div class=\"wp-block-image eplus-wrapper\"><figure class=\"aligncenter size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"425\" src=\"https:\/\/kekkan-biologics.com\/wp-content\/uploads\/2022\/02\/image-3-1024x425.png\" alt=\"\" class=\"wp-image-227\" srcset=\"https:\/\/kekkan-biologics.com\/wp-content\/uploads\/2022\/02\/image-3-1024x425.png 1024w, https:\/\/kekkan-biologics.com\/wp-content\/uploads\/2022\/02\/image-3-300x125.png 300w, https:\/\/kekkan-biologics.com\/wp-content\/uploads\/2022\/02\/image-3-768x319.png 768w, https:\/\/kekkan-biologics.com\/wp-content\/uploads\/2022\/02\/image-3-1536x637.png 1536w, https:\/\/kekkan-biologics.com\/wp-content\/uploads\/2022\/02\/image-3.png 1689w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><\/div>\n\n\n\n<h2 class=\"has-secondary-color has-text-color eplus-wrapper wp-block-heading\" id=\"publications\">Publications<\/h2>\n\n\n\n<p class=\"has-primary-color has-text-color has-large-font-size eplus-wrapper\"><strong>2022<\/strong><\/p>\n\n\n<ul class=\" eplus-wrapper eplus-styles-uid-a82c7c\"><li>Pagnuzzi-Boncompagni, M, Picco, V, Vial, V, Planas-Bielsa, V, Vandenberghe, A, Daubon, T, Derieppe, MA, Montemagno, C, Durivault, J, Gr\u00e9pin, R, Martial, S, Doyen, J, Gavard, J and Pag\u00e8s, G. Cancers 2022 ;14(1):70.<\/li><\/ul>\n\n\n<p class=\"has-primary-color has-text-color has-large-font-size eplus-wrapper\"><strong>2021<\/strong><\/p>\n\n\n\n<p class=\" eplus-wrapper\">1-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hagege A, Ambrosetti D, Boyer J, Bozec A, Doyen J, Chamorey E, He X, Bourget I, Rousset J, Saada E, Rastoin O, Parola J, Luciano F, Cao Y,&nbsp;<strong>Pag\u00e8s G*<\/strong>, Dufies M* (*codirection of the work).&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34646387\/\" target=\"_blank\" rel=\"noreferrer noopener\">The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy<\/a>.&nbsp;Theranostics. 2021 Sep 21;11(19):9571-9586.<\/p>\n\n\n\n<p class=\" eplus-wrapper\">2-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dumond A, Montemagno C, Vial V, Gr\u00e9pin R,&nbsp;<strong>Pag\u00e8s G<\/strong>.&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34067671\/\" target=\"_blank\" rel=\"noreferrer noopener\">Anti-Vascular Endothelial Growth Factor C Antibodies Efficiently Inhibit the Growth of Experimental Clear Cell Renal Cell Carcinomas.&nbsp;<\/a>Cells. 2021 May 17;10(5):1222.<\/p>\n\n\n\n<p class=\" eplus-wrapper\">3-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dumond, A, Brachet, E, Durivault, J, Vial, V, Puszko, AK, Lepelletier, Y, Montemagno, C, Pagnuzzi-Boncompagni, M, Hermine, O, Garbay, C, Lagarde, N, Montes, M, Demange, L, Gr\u00e9pin, R and&nbsp;<strong>Pag\u00e8s, G<\/strong>. Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma Journal of Experimental &amp; Clinical Cancer Research 2021 40:33<\/p>\n\n\n\n<p class=\" eplus-wrapper\">4-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dufies M, Verbiest A, Cooley L, Ndiaye P, Viotti J, He X, Nottet N, Souleyreau W, Hagege A, Torrino S, Parola J, Giuliano S, Borchiellini D, Schiappa R, Mograbi B, Zucman-Rossi J, Bensalah K, Ravaud A, Auberger P, Bikfalvi A, Chamorey E, Rioux-Leclercq N, Mazure N, Beuselinck B, Co Y, Bernhard JC, Ambrosetti D and&nbsp;<strong>Pag\u00e8s G<\/strong>. A novel mechanism of HIF2-dependent Plk1-mediated metastasis and drug resistance of clear cell Renal Cell Carcinoma. Commun Biol.&nbsp;2021 Feb 5;4(1):166.<\/p>\n\n\n\n<p class=\" eplus-wrapper\">5-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ambrosetti D, Coutts M, Paoli C, Durand M, Borchiellini D, Montemagno C, Rastoin O, Borderie A, Grepin R, Rioux-Leclercq N, Bernhard JC,&nbsp;<strong>Pag\u00e8s G*,<\/strong>&nbsp;Dufies M*.&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34107167\/\" target=\"_blank\" rel=\"noreferrer noopener\">Cancer associated fibroblasts in Renal Cell Carcinoma: implication in prognosis and resistance to antiangiogenic therapy.&nbsp;<\/a>&nbsp;BJU Int. 2021 Jun 9. doi: 10.1111\/bju.15506.<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34203923\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/p>\n\n\n\n<p class=\" eplus-wrapper\">6-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cooley LS, Rudewicz J, Souleyreau W, Emanuelli A, Alvarez-Arenas A, Clarke K, Falciani F, Dufies M, Lambrechts D, Modave E, Chalopin-Fillot D, Pineau R, Ambrosetti D, Bernhard JC, Ravaud A, N\u00e9grier S, Ferrero JM,&nbsp;<strong>Pag\u00e8s G<\/strong>, Benzekry S, Nikolski M, Bikfalvi A.&nbsp;Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression&nbsp;Mol Cancer. 2021 Oct 20;20(1):136.<\/p>\n\n\n\n<p class=\"has-primary-color has-text-color has-large-font-size eplus-wrapper\"><strong>2020<a><\/a><\/strong><\/p>\n\n\n\n<p class=\" eplus-wrapper\"><a><\/a><a><\/a><a>1-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Montemagno C,<\/a>&nbsp;Hagege A,&nbsp;Borchiellini D, Thamphya B, Rastoin O, Ambrosetti D, Iovanna J,&nbsp;Rioux-Leclercq N,&nbsp;Porta C, Negrier S,&nbsp;Ferrero JM,&nbsp;Chamorey E,&nbsp;<strong>Pag\u00e8s G<\/strong><sup>*<\/sup>&nbsp;and Dufies M* (* co-direction of the work).&nbsp;Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma&nbsp;Oncoimmunology. 2020 Nov 25;9(1):1846901.<\/p>\n\n\n\n<p class=\" eplus-wrapper\">2-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Penco-Campillo M, Comoglio Y, Feliz Morel \u00c1J, Hanna R, Durivault J, Leloire M, Mejias B, Pagnuzzi M, Morot A, Burel-Vandenbos F, Selby M, Williamson D, Clifford SC, Claren A, Doyen J, Picco V, Martial S,&nbsp;<strong>Pag\u00e8s G<\/strong>.&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33067561\/\" target=\"_blank\" rel=\"noreferrer noopener\">VEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells.<\/a>&nbsp;Commun Biol. 2020 Oct 16;3(1):579.<\/p>\n\n\n\n<p class=\" eplus-wrapper\"><a>3-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gr\u00e9pin R, Guyot M, Dumond A, Durivault J, Ambrosetti D, Roussel JF, Dupr\u00e9 F, Quintens H,&nbsp;<strong>Pag\u00e8s G<\/strong>.&nbsp;<\/a><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31938054\" target=\"_blank\" rel=\"noreferrer noopener\">The combination of bevacizumab\/Avastin and erlotinib\/Tarceva is relevant for the treatment of metastatic renal cell carcinoma : the role of a synonymous mutation of the EGFR receptor.<\/a>&nbsp;Theranostics. 2020 Jan 1;10(3):1107-1121.<\/p>\n\n\n\n<p class=\" eplus-wrapper\"><a>4-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Montemagno C,&nbsp;<strong>Pag\u00e8s G<\/strong>. R<\/a><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32775327\/\" target=\"_blank\" rel=\"noreferrer noopener\">esistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs.&nbsp;<\/a>&nbsp;Front Cell Dev Biol. 2020 Jul 7;8:584.<\/p>\n\n\n\n<p class=\" eplus-wrapper\">5-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dumond A,&nbsp;<strong>Pag\u00e8s G<\/strong>.&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32766254\/\" target=\"_blank\" rel=\"noreferrer noopener\">Neuropilins, as Relevant Oncology Target: Their Role in the Tumoral Microenvironment.&nbsp;<\/a>&nbsp;Front Cell Dev Biol. 2020 Jul 17; 8:662.<\/p>\n\n\n\n<p class=\" eplus-wrapper\">6-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rastoin O,&nbsp;<strong>Pag\u00e8s G<\/strong>, Dufies, M,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32610682\/\" target=\"_blank\" rel=\"noreferrer noopener\">Experimental Models in Neovascular Age Related Macular Degeneration.&nbsp;<\/a>Int J Mol Sci. 2020 Jun 29;21(13):4627.<\/p>\n\n\n\n<p class=\" eplus-wrapper\">7-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dumond A, Demange L,&nbsp;<strong>Pag\u00e8s G<\/strong>.&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32452371\/\" target=\"_blank\" rel=\"noreferrer noopener\">[Neuropilins: relevant therapeutic targets to improve the treatment of cancers].&nbsp;<\/a>Med Sci (Paris). 2020 May;36(5):487-496.<\/p>\n\n\n\n<p class=\" eplus-wrapper\">8-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fabbri L, Dufies M, Lacas-Gervais S, Gardie B, Gad-Lapiteau S, Parola J, Nottet N, Meyenberg Cunha de Padua M, Contenti J, Borchiellini D, Ferrero JM, Leclercq NR, Ambrosetti D, Mograbi B, Richard S, Viotti J, Chamorey E, Sadaghianloo N, Rouleau M, Craigen WJ, Mari B, Clavel S,&nbsp;<strong>Pag\u00e8s G<\/strong>, Pouyss\u00e9gur J, Bost F, Mazure NM.&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32194829\/\" target=\"_blank\" rel=\"noreferrer noopener\">Identification of a new aggressive axis driven by ciliogenesis and absence of VDAC1-\u0394C in clear cell Renal Cell Carcinoma patients.&nbsp;<\/a>Theranostics. 2020 Feb 3;10(6):2696-2713.<\/p>\n\n\n\n<p class=\"has-primary-color has-text-color has-large-font-size eplus-wrapper\"><strong>2019<\/strong><\/p>\n\n\n\n<p class=\" eplus-wrapper\"><a>1-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/a><a href=\"http:\/\/thno.org\/v09p0661\" target=\"_blank\" rel=\"noreferrer noopener\">Ndiaye PD, Dufies M, Giuliano S, Douguet L, Gr\u00e9pin R, Durivault J, Lenormand P, Glisse N, Mintcheva J, Vouret-Craviari V, Mograbi B, Wurmser M, Ambrosetti D, Rioux-Leclercq N, Maire P,&nbsp;<strong>Pag\u00e8s G<\/strong>. VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness.&nbsp;<em>Theranostics<\/em>&nbsp;2019; 9(3):661-675.<\/a><\/p>\n\n\n\n<p class=\" eplus-wrapper\">2-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ndiaye PD,&nbsp;<strong>Pag\u00e8s G<\/strong>.&nbsp;<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30774080\" target=\"_blank\" rel=\"noreferrer noopener\">VEGF-C and lymphatic vessels: a double-edged sword in tumor development and metastasis.<\/a>&nbsp;Med Sci (Paris). 2019 Feb;35(2):132-137.<\/p>\n\n\n\n<p class=\" eplus-wrapper\">3-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Brachet E, Dumond A, Liu WQ, Fabre M, Selkti M, Raynaud F, Hermine O, Benhida R, Belmont P, Garbay C, Lepelletier Y, Ronco C,&nbsp;<strong>Pag\u00e8s G<\/strong>, Demange L.&nbsp;<a rel=\"noreferrer noopener\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31699610\/\" target=\"_blank\">Synthesis, 3D-structure and stability analyses of NRPa-308, a new promising anti-cancer agent.&nbsp;<\/a>Bioorg Med Chem Lett. 2019 Dec 15;29(24):126710.<\/p>\n\n\n\n<p class=\"has-primary-color has-text-color has-large-font-size eplus-wrapper\"><strong>2018<\/strong><\/p>\n\n\n\n<p class=\" eplus-wrapper\"><a>1-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>Pag\u00e8s, G<\/strong><\/a>. The path to \u00ab the Golden Age \u00bb for the treatment of metastatic renal cell carcinoma. Oncotarget 2018 3;9(60):31564-31565.<sup><\/sup><\/p>\n\n\n\n<p class=\" eplus-wrapper\">2-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dufies,M, Nollet, M, Ambrosetti, D, Viotti, J, Borchiellini, D, Parola, J, Helley-Russick, D, Ravaud, A, Bernhard, JC, Bardin, N, Dignat-george, F, Rioux-Leclercq, N, Oudard, S, Negrier, S, Ferrero, JM, Chamorey, E, Blot-Chabaud,M*and&nbsp;<strong>Pag\u00e8s, G<\/strong>. Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma. Theranostic, 2018, 28;8(9):2447-2458.<sup><\/sup><\/p>\n\n\n\n<p class=\" eplus-wrapper\">3-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Polena, H*, Creuzet J*, Dufies M*, Sidib\u00e9 A, Khalil-Mgharbel1 A, Salomon A, Deroux A, Quesada JL, Roelants C, Filhol O, Cochet C, Blanc E, Ferlay-Segura E, Borchiellini D, Ferrero JM, Escudier B, N\u00e9grier S,&nbsp;<strong>Pag\u00e8s, G<\/strong>*, Vilgrain, I*. (* Co-premiers, \u00a4 Co-derniers auteurs). Br J Cancer, 2018, 118(9):1179-1188.<sup><\/sup><\/p>\n\n\n\n<p class=\" eplus-wrapper\">4-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ambrosetti D, Dufies M, Dadone B, Durand M, Borchiellini D, Amiel J, Pouyssegur J, Rioux-Leclercq N,&nbsp;<strong>Pages G<\/strong>, Burel-Vandenbos F, Mazure NM.&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29481555\/\" target=\"_blank\" rel=\"noreferrer noopener\">The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma.&nbsp;<\/a>PLoS One. 2018 Feb 26;13(2):e0193477<\/p>\n\n\n\n<p class=\"has-primary-color has-text-color has-large-font-size eplus-wrapper\"><strong>2017<\/strong><\/p>\n\n\n\n<p class=\" eplus-wrapper\"><a>1-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dufies, M*, Giuliano, S*, Viotti, J, Borchiellini, D, Cooley, L, Ambrosetti, D, Guyot, M, Diogop Ndiaye, P, Parola, J, Claren, A, Schiappa, R, Gal, J, Frangeul, A, Jacquel, A, Cassuto, O, Gr\u00e9pin, R, Auberger, P, Bikfalvi, A, Milano, G, Escudier, B, Rioux-Leclercq, N, Porta, C, N\u00e9grier, S, Chamorey, E, Ferrero, JM and&nbsp;<\/a><strong>Pag\u00e8s, G<\/strong>. CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas, Br J Cancer 2017, 1;77(5):1212-1226.<\/p>\n\n\n\n<p class=\" eplus-wrapper\">2-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lupu-Plesu, M*, Claren, A*, Martial, S, Diogop N\u2019Diaye, P, Lebrigand, K, Pons, N, Ambrosetti, D, Peyrottes, I, Feuillade, J, H\u00e9rault, J, Dufies, M, Doyen. Jand&nbsp;<strong>Pag\u00e8s, G<\/strong>. Effects of proton versus photon irradiation on (lymph)angiogenic, inflammatory, proliferative and anti-tumor immune responses in head and neck squamous cell carcinoma, Oncogenesis 2017 3;6(7):e354.<\/p>\n\n\n\n<p class=\" eplus-wrapper\">3-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dufies M, Giuliano S, Ambrosetti D, Claren A, Diogop Ndiaye P, Mastri M, Moghrabi W, Cooley LS, Ettaiche M, Chamorey E, Parola J, Vial V, Lupu-Plesu M, Bernhard JC, Ravaud A, Borchiellini D, Ferrero JM, Bikfalvi A, Ebos JM, Khabar KS, Grepin R,&nbsp;<strong>Pag\u00e8s G<\/strong>.&nbsp;<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28087600\" target=\"_blank\" rel=\"noreferrer noopener\">Sunitinib stimulates expression of VEGFC by tumor cells and promotes lymphangiogenesis in clear cell renal cell carcinomas.<\/a>&nbsp;Cancer Res. 2017 Mar 1;77(5):1212-1226<\/p>\n\n\n\n<p class=\" eplus-wrapper\">4-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Guyot M, Hilmi C, Ambrosetti D, Merlano M, Lo Nigro C, Durivault J, Gr\u00e9pin R,&nbsp;<strong>Pag\u00e8s G<\/strong>&nbsp;<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27999187\" target=\"_blank\" rel=\"noreferrer noopener\">Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.<\/a>&nbsp;Oncotarget. 2017 Feb 7;8(6):9174-9188<\/p>\n\n\n\n<p class=\" eplus-wrapper\">5-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Masoud V,&nbsp;<strong>Pag\u00e8s G.<\/strong>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28439493\/\" target=\"_blank\" rel=\"noreferrer noopener\">Targeted therapies in breast cancer: New challenges to fight against resistance.&nbsp;<\/a>World J Clin Oncol. 2017 Apr 10;8(2):120-134.<\/p>\n\n\n\n<p class=\" eplus-wrapper\">6-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ambrosetti D, Dufies M, Dadone B, Durand M, Borchiellini D, Amiel J, Pouyssegur J, Rioux-Leclercq N,&nbsp;<strong>Pag\u00e8s G<\/strong>, Burel-Vandenbos F, Mazure NM.&nbsp;<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29481555\" target=\"_blank\" rel=\"noreferrer noopener\">The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma.<\/a>&nbsp;PLoS One. 2018 Feb 26;13(2):e0193477.<\/p>\n\n\n\n<p class=\"has-primary-color has-text-color has-large-font-size eplus-wrapper\"><strong>Patents<\/strong><\/p>\n\n\n\n<p class=\" eplus-wrapper\">1-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Montemagno, C, Durivault, J,&nbsp;<strong>Pag\u00e8s, G<\/strong>&nbsp;(2020).&nbsp;New splice variant isoform of VEGF.&nbsp;EP20204454.1<\/p>\n\n\n\n<p class=\" eplus-wrapper\">2-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dumond, A, Gr\u00e9pin, R<strong>, Pag\u00e8s, G<\/strong>&nbsp;(2020).&nbsp;New anti-VEGFC antibodies and uses thereof: EP20305296.4.<\/p>\n\n\n\n<p class=\" eplus-wrapper\">3-&nbsp;&nbsp;&nbsp;Gr\u00e9pin, R,&nbsp;<strong>Pag\u00e8s, G<\/strong>&nbsp;(2013): Anti-CXCL1, CXCL7 and CXCL8 antibodies and their applications. WO 2014\/184384.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Our Approach Malignant tumors need blood vessels to get nutrients and oxygen, and they use lymphatic vessels to metastasize. Blocking validated targets in angiogenesis and lymphangiogenesis with highly specific and safe antibodies, deprives tumors of their ability to grow and metastasize. KB Platform Sophisticated target selection and mAb development designed to address multiple pathological mechanisms [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-large-header","meta":{"editor_plus_copied_stylings":"{}","footnotes":""},"_links":{"self":[{"href":"https:\/\/kekkan-biologics.com\/index.php\/wp-json\/wp\/v2\/pages\/224"}],"collection":[{"href":"https:\/\/kekkan-biologics.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/kekkan-biologics.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/kekkan-biologics.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kekkan-biologics.com\/index.php\/wp-json\/wp\/v2\/comments?post=224"}],"version-history":[{"count":12,"href":"https:\/\/kekkan-biologics.com\/index.php\/wp-json\/wp\/v2\/pages\/224\/revisions"}],"predecessor-version":[{"id":300,"href":"https:\/\/kekkan-biologics.com\/index.php\/wp-json\/wp\/v2\/pages\/224\/revisions\/300"}],"wp:attachment":[{"href":"https:\/\/kekkan-biologics.com\/index.php\/wp-json\/wp\/v2\/media?parent=224"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}